Akums Drugs and Pharmaceuticals Limited

rs,

bai – 400 051 To, The Listing Department BSE Limited Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Disclosure under R

1%

tinue Akums’ witnessed double digit volume growth though IPM MAT Mar ‘26 volumes grew less than 1%* API prices saw correction though some stability witnessed in Q4. Overall capacity utilization

44%

s saw correction though some stability witnessed in Q4. Overall capacity utilization improved to 44% for FY26 driven by strong volume growth. New facilities ramping up steadily – all lines of new I

45 million

arting FY28 onwards JV with the Govt. of the Republic of Zambia (GRZ) • Total project cost ~.USD 45 million, with Akums owning 51% stake and GRZ holding remaining 49% • JV to procure medicines worth USD 25

51%

he Govt. of the Republic of Zambia (GRZ) • Total project cost ~.USD 45 million, with Akums owning 51% stake and GRZ holding remaining 49% • JV to procure medicines worth USD 25 million per annum from

49%

GRZ) • Total project cost ~.USD 45 million, with Akums owning 51% stake and GRZ holding remaining 49% • JV to procure medicines worth USD 25 million per annum from Akums for FY27 and FY28 Europe – f

25 million

on, with Akums owning 51% stake and GRZ holding remaining 49% • JV to procure medicines worth USD 25 million per annum from Akums for FY27 and FY28 Europe – focused approach to drive next leg of growth •

3.2%

ntinues • Total cumulative DCGI approvals count at 1,056 till FY26 • R&D spent remained healthy at 3.2% of revenue Automation to drive operational efficiency • SAP S/4HANA transformation to enable impr

11.2%

ights Consolidated Performance Segment Break-up 1,193 cr 1,050 cr Total Income Total Income (+11.2% YoY) (+0.3% YoY) 187 cr 121 cr 15.7% 11.6% EBITDA Adj. EBITDA (+67.8% YoY) (-130 bps YoY) 81

0.3%

dated Performance Segment Break-up 1,193 cr 1,050 cr Total Income Total Income (+11.2% YoY) (+0.3% YoY) 187 cr 121 cr 15.7% 11.6% EBITDA Adj. EBITDA (+67.8% YoY) (-130 bps YoY) 81 cr 54 cr 6.8%

15.7%

Break-up 1,193 cr 1,050 cr Total Income Total Income (+11.2% YoY) (+0.3% YoY) 187 cr 121 cr 15.7% 11.6% EBITDA Adj. EBITDA (+67.8% YoY) (-130 bps YoY) 81 cr 54 cr 6.8% 5.1% PAT (-45.6% YoY) Adj

11.6%

-up 1,193 cr 1,050 cr Total Income Total Income (+11.2% YoY) (+0.3% YoY) 187 cr 121 cr 15.7% 11.6% EBITDA Adj. EBITDA (+67.8% YoY) (-130 bps YoY) 81 cr 54 cr 6.8% 5.1% PAT (-45.6% YoY) Adj. PAT